Clearside Biomedical Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.853
- Today's High:
- $0.899
- Open Price:
- $0.8537
- 52W Low:
- $0.9
- 52W High:
- $1.855
- Prev. Close:
- $0.87
- Volume:
- 105838
Company Statistics
- Market Cap.:
- $75.23 million
- Book Value:
- 0.044
- Revenue TTM:
- $984000
- Operating Margin TTM:
- -3072.76%
- Gross Profit TTM:
- $1.12 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -46.8%
- Return on Equity TTM:
- -201.05%
Company Profile
Clearside Biomedical Inc had its IPO on 2016-06-02 under the ticker symbol CLSD.
The company operates in the Healthcare sector and Biotechnology industry. Clearside Biomedical Inc has a staff strength of 36 employees.
Stock update
Shares of Clearside Biomedical Inc opened at $0.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.85 - $0.9, and closed at $0.85.
This is a -1.95% slip from the previous day's closing price.
A total volume of 105,838 shares were traded at the close of the day’s session.
In the last one week, shares of Clearside Biomedical Inc have slipped by -6.26%.
Clearside Biomedical Inc's Key Ratios
Clearside Biomedical Inc has a market cap of $75.23 million, indicating a price to book ratio of 3.927 and a price to sales ratio of 2.6392.
In the last 12-months Clearside Biomedical Inc’s revenue was $984000 with a gross profit of $1.12 million and an EBITDA of $-30122000. The EBITDA ratio measures Clearside Biomedical Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Clearside Biomedical Inc’s operating margin was -3072.76% while its return on assets stood at -46.8% with a return of equity of -201.05%.
In Q1, Clearside Biomedical Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98.8%.
Clearside Biomedical Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clearside Biomedical Inc’s profitability.
Clearside Biomedical Inc stock is trading at a EV to sales ratio of 0.7441 and a EV to EBITDA ratio of -4.8278. Its price to sales ratio in the trailing 12-months stood at 2.6392.
Clearside Biomedical Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $44.70 million
- Total Liabilities
- $4.98 million
- Operating Cash Flow
- $-115000.00
- Capital Expenditure
- $115000
- Dividend Payout Ratio
- 0%
Clearside Biomedical Inc ended 2024 with $44.70 million in total assets and $0 in total liabilities. Its intangible assets were valued at $44.70 million while shareholder equity stood at $2.70 million.
Clearside Biomedical Inc ended 2024 with $0 in deferred long-term liabilities, $4.98 million in other current liabilities, 61000.00 in common stock, $-297718000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $41.42 million and cash and short-term investments were $41.42 million. The company’s total short-term debt was $356,000 while long-term debt stood at $0.
Clearside Biomedical Inc’s total current assets stands at $42.57 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.59 million and inventory worth $0.
In 2024, Clearside Biomedical Inc's operating cash flow was $-115000.00 while its capital expenditure stood at $115000.
Comparatively, Clearside Biomedical Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.85
- 52-Week High
- $1.855
- 52-Week Low
- $0.9
- Analyst Target Price
- $5.6
Clearside Biomedical Inc stock is currently trading at $0.85 per share. It touched a 52-week high of $1.855 and a 52-week low of $1.855. Analysts tracking the stock have a 12-month average target price of $5.6.
Its 50-day moving average was $1.05 and 200-day moving average was $1.17 The short ratio stood at 4.79 indicating a short percent outstanding of 0%.
Around 745.2% of the company’s stock are held by insiders while 2813% are held by institutions.
Frequently Asked Questions About Clearside Biomedical Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.